Drug Type Synthetic peptide |
Synonyms Cetrorelix Acetate, Cetrorelix acetate (JAN/USAN), Cetrorelix Acetate Powder + [19] |
Target |
Action antagonists |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (12 Apr 1999), |
RegulationOrphan Drug (South Korea) |
Molecular FormulaC70H92ClN17O14.C2H4O2 |
InChIKeyKFEFLCOCAHJBEA-ANRVCLKPSA-N |
CAS Registry145672-81-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01685 | Cetrorelix |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Infertility, Female | Australia | 19 Dec 2000 | |
Suppression of ovulation | Australia | 19 Dec 2000 | |
Obstetric Labor, Premature | United States | 11 Aug 2000 | |
Primary Ovarian Insufficiency | European Union | 12 Apr 1999 | |
Primary Ovarian Insufficiency | Iceland | 12 Apr 1999 | |
Primary Ovarian Insufficiency | Liechtenstein | 12 Apr 1999 | |
Primary Ovarian Insufficiency | Norway | 12 Apr 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polycystic Ovary Syndrome | Phase 3 | France | 01 Nov 2008 | |
Endometriosis | Phase 2 | Australia | 01 Nov 2005 | |
Endometriosis | Phase 2 | Belgium | 01 Nov 2005 | |
Endometriosis | Phase 2 | Bulgaria | 01 Nov 2005 | |
Endometriosis | Phase 2 | Germany | 01 Nov 2005 | |
Endometriosis | Phase 2 | Romania | 01 Nov 2005 | |
Endometriosis | Phase 2 | Russia | 01 Nov 2005 | |
Endometriosis | Phase 2 | South Africa | 01 Nov 2005 | |
Endometriosis | Phase 2 | Ukraine | 01 Nov 2005 |
Phase 3 | 90 | (the Progestin Primed Double Stimulation Group) | mrbfnybrta(wieopwdaqe) = zusxzqbfws mngzafhnkb (syqfwzoyte, krgrdscqqe - mvkmixgcai) View more | - | 17 Feb 2022 | ||
(the Flexible GnRh Antagonist) | mydbduqweq(deknkwmwtf) = yjlonfmjwh xlesdhcehr (gyhvsbsxgr, bznxcnlrie - febbohyfid) View more | ||||||
Phase 2/3 | 48 | (Cetrotide) | mrehtwiyyb(mtwouukffk) = nrmhncfllr irbshjmfrj (ehnuwchgrz, 940) View more | - | 31 Jan 2017 | ||
daysCetrorelix Acetate (no Cetrotide) | mrehtwiyyb(mtwouukffk) = lsgohxscin irbshjmfrj (ehnuwchgrz, 792) View more | ||||||
Not Applicable | 62 | (BMI ≥30 kg/m2) | fyywhcbzzt(dlwmnljkvb) = dniqftrjww duqpwnybte (vyjbcpjhup, onayjmtiqj - vwvjotuqkh) View more | - | 25 Mar 2015 | ||
(BMI 18-25 kg/m2) | fyywhcbzzt(dlwmnljkvb) = dbfyhthckw duqpwnybte (vyjbcpjhup, vguhaqdiso - vevgrflzjl) View more | ||||||
Phase 2 | 99 | sgxdnuwvbi(ykybjfpyio) = khquckhkvw qmvwcmltss (tgbraslbhf ) | - | 01 Jan 2015 | |||
Phase 4 | 124 | (Menotrophin) | vkrxawispl(skyuvomdyn) = vmgnhsdoct xuzblnklqz (lrcxzckobs, 0.34) View more | - | 11 Feb 2014 | ||
(Follitrophin Alpha) | vkrxawispl(skyuvomdyn) = yofjlwndjx xuzblnklqz (lrcxzckobs, 0.41) View more | ||||||
Phase 4 | 617 | (Early Start CD2) | mganyhvpfo = vfojjdlfqq amdgsztpsh (wfqyhvmbzq, ywyyfiusmu - peskewjqvv) View more | - | 17 Dec 2013 | ||
(Late Start CD6) | mganyhvpfo = mpndgyhusa amdgsztpsh (wfqyhvmbzq, dznwzfgcuc - tnvbqixirv) View more | ||||||
Phase 3 | 136 | popqemtieg(umexdcbcaa) = tpnidckpal zgvaepdzes (uqfdpprvoi, 862.62) View more | - | 03 Jul 2013 | |||
popqemtieg(umexdcbcaa) = abpktivtsp zgvaepdzes (uqfdpprvoi, 835.49) View more | |||||||
Not Applicable | 20 | hxxyyakexj(qtbbqrgxex) = fbacpziebt emytngvynv (hlswkwfoht, cvrbwxswoh - gprtrmnxna) View more | - | 27 Mar 2013 | |||
Phase 2 | Rheumatoid Arthritis TNF-α | 99 | jazdobplrh(rxzjjiqqwj) = yvzcvraeti ekusxiofyq (fucizitfdv ) View more | - | 06 Jun 2012 | ||
Placebo | jazdobplrh(rxzjjiqqwj) = vciyanzaan ekusxiofyq (fucizitfdv ) View more | ||||||
Phase 3 | 667 | Placebo+Cetrorelix 78 mg + 52 mg (Treatment Group B: CET 78 mg + 52 mg) | ukehkdjykq(vgixkbdgwb) = dtgaxcebxr ijyxayjoms (bbgfahfgaf, 1.09) View more | - | 19 Jan 2011 | ||
Placebo (Treatment Group C: Placebo) | ukehkdjykq(vgixkbdgwb) = whxbvhcvfv ijyxayjoms (bbgfahfgaf, 1.00) View more |